AstraZeneca Gets CDSCO Nod to Market Enhertu for New Breast Cancer Indication Written By Parthika Patel8 Aug 2026 9:00 PM ISTBengaluru: AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organization (CDSCO), Directorate General...
CDSCO Approves AstraZeneca's Enhertu for Neoadjuvant HER2-Positive Breast Cancer Written By Parthika Patel28 July 2026 10:16 PM ISTNew Delhi: AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation (CDSCO), Directorate General...
FDA Expands Enhertu Approval for Early-Stage HER2-Positive Breast Cancer Written By Dr. Kamal Kant Kohli19 May 2026 7:30 AM ISTThe FDA has approved two new indications for trastuzumab deruxtecan (Enhertu) in patients with early-stage HER2-positive breast cancer. One approval...
AstraZeneca-Daiichi Sankyo Enhertu gets USFDA Breakthrough Therapy Designation in HER2-positive early breast cancer Written By Ruchika Sharma22 Dec 2025 1:30 PM ISTCambridge: AstraZeneca and Daiichi Sankyo has announced that Enhertu (trastuzumab deruxtecan) has been granted Breakthrough Therapy Designation (BTD)...
AstraZeneca-Daiichi Sankyo Enhertu Combo wins USFDA approval for 1st-line HER2-Positive Metastatic Breast Cancer Written By Ruchika Sharma16 Dec 2025 12:30 PM ISTCambridge: AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) in combination with pertuzumab has been approved in the US for...
Racket Selling Expired, Relabelled Cancer Drugs Including Keytruda, Enhertu Busted in UP, 3 Held Written By Parthika Patel30 Nov 2025 12:30 PM ISTGhaziabad: In a crackdown, Ghaziabad police have busted a racket dealing in expired and relabelled cancer medicines, arresting three men after seizing...
AstraZeneca Pharma India gains CDSCO permission for Enhertu in HER2-positive solid tumours Written By Ruchika Sharma4 Oct 2025 11:27 AM ISTBangalore: AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation (CDSCO), Directorate...
AstraZeneca-Daiichi Sankyo get USFDA grants priority review for Enhertu combo for 1st line HER2+ Breast cancer treatment Written By Ruchika Sharma24 Sept 2025 12:46 PM ISTCambridge: AstraZeneca and Daiichi Sankyo's supplemental Biologics License Application (sBLA) for Enhertu (trastuzumab deruxtecan) in combination...
AstraZeneca Pharma India gets CDSCO approval for Enhertu for new breast cancer indication Written By Ruchika Sharma9 May 2025 3:31 PM ISTBangalore: AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation (CDSCO), Directorate...
Roche bags USFDA nod for companion diagnostic to identify patients with HER2-ultralow metastatic breast cancer eligible for Enhertu Written By Ruchika Sharma1 Feb 2025 12:30 PM ISTBasel: Roche has announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion for the PATHWAY anti-HER2/neu (4B5)...
AstraZeneca-Daiichi Sankyo Enhertu gets USFDA approval for HER2-ultralow metastatic breast cancer Written By Ruchika Sharma28 Jan 2025 2:30 PM ISTAstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with...
Addition of AstraZeneca breast cancer drug Enhertu to China state insurance list Written By Ruchika Sharma29 Nov 2024 5:29 PM ISTChina: Enhertu, a blockbuster breast cancer drug of AstraZeneca, will be included in China's state-run health insurance scheme from January 1, as per...
